{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:32:37Z","timestamp":1787956357789,"version":"build-2784847793"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain & Behavior Research Foundation","doi-asserted-by":"publisher","award":["28445"],"award-info":[{"award-number":["28445"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Grant from the Novartis Foundation","award":["20A058"],"award-info":[{"award-number":["20A058"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Side effects of antipsychotic drugs play a key role in nonadherence of treatment in schizophrenia spectrum disorders (SSD). While clinical observations suggest that side effect variability between patients may be considerable, statistical evidence is required to confirm this. Here, we hypothesized to find larger side effect variability under treatment compared with control. We included double-blind, placebo-controlled, randomized controlled trials (RCTs) of adults with a diagnosis of SSD treated with 1 out of 14 antipsychotics. Standard deviations of the pre-post treatment differences of weight gain, prolactin levels, and corrected QT (QTc) times were extracted. The outcome measure was the variability ratio of treatment to control for individual antipsychotic drugs and the overall variability ratio of treatment to control across RCTs. Individual variability ratios were weighted by the inverse-variance method and entered into a random-effects model. We included N = 16 578 patients for weight gain, N = 16 633 patients for prolactin levels, and N = 10 384 patients for QTc time. Variability ratios (VR) were significantly increased for weight gain (VR = 1.08; 95% CI: 1.02\u20131.14; P = .004) and prolactin levels (VR = 1.38; 95% CI: 1.17\u20131.62; P &amp;lt; .001) but did not reach significance for QTc time (VR = 1.05; 95% CI: 0.98\u20131.12; P = 0.135). We found marked differences between individual antipsychotics and increased variability in side effects in patients under treatment with antipsychotics suggesting that subgroups of patients or individual patients may benefit from treatment allocation through stratified or personalized medicine.<\/jats:p>","DOI":"10.1093\/schbul\/sbab078","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T16:20:12Z","timestamp":1622737212000},"page":"1601-1610","source":"Crossref","is-referenced-by-count":23,"title":["Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance"],"prefix":"10.1093","volume":"47","author":[{"given":"Maria S","family":"Neumeier","sequence":"first","affiliation":[{"name":"University Hospital of Psychiatry Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Homan","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Vetter","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Kane","sequence":"additional","affiliation":[{"name":"Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA"},{"name":"Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Huhn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-148X","authenticated-orcid":false,"given":"Philipp","family":"Homan","sequence":"additional","affiliation":[{"name":"University Hospital of Psychiatry Zurich, Zurich, Switzerland"},{"name":"Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA"},{"name":"Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, NY, USA"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"7","key":"2021102118064328500_CIT0001","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur Psychiatry."},{"issue":"3","key":"2021102118064328500_CIT0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry."},{"issue":"1-2","key":"2021102118064328500_CIT0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","article-title":"A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders","volume":"225","author":"Sendt","year":"2015","journal-title":"Psychiatry Res."},{"key":"2021102118064328500_CIT0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cpr.2016.10.009","article-title":"A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis","volume":"51","author":"Wade","year":"2017","journal-title":"Clin Psychol Rev."},{"issue":"11","key":"2021102118064328500_CIT0005","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41386-019-0464-y","article-title":"Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis","volume":"44","author":"Homan","year":"2019","journal-title":"Neuropsychopharmacology."},{"issue":"10202","key":"2021102118064328500_CIT0006","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"issue":"10","key":"2021102118064328500_CIT0007","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamapsychiatry.2019.1530","article-title":"Evaluation of differences in individual treatment response in schizophrenia spectrum disorders: a meta-analysis","volume":"76","author":"Winkelbeiner","year":"2019","journal-title":"JAMA Psychiatry."},{"issue":"8","key":"2021102118064328500_CIT0008","doi-asserted-by":"crossref","first-page":"e0237950","DOI":"10.1371\/journal.pone.0237950","article-title":"Individual response to antidepressants for depression in adults-a meta-analysis and simulation study","volume":"15","author":"Munkholm","year":"2020","journal-title":"PLoS One."},{"issue":"7","key":"2021102118064328500_CIT0009","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/sim.6739","article-title":"Mastering variation: variance components and personalised medicine","volume":"35","author":"Senn","year":"2016","journal-title":"Stat Med."},{"issue":"7733","key":"2021102118064328500_CIT0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/d41586-018-07535-2","article-title":"Statistical pitfalls of personalized medicine","volume":"563","author":"Senn","year":"2018","journal-title":"Nature."},{"issue":"30","key":"2021102118064328500_CIT0011","article-title":"Does evidence support the high expectations placed in precision medicine? A bibliographic review","volume":"7","author":"Cort\u00e9s","year":"2019","journal-title":"F1000Research."},{"key":"2021102118064328500_CIT0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/2041-210X.12309","article-title":"Meta-analysis of variation: ecological and evolutionary applications and beyond","volume":"6","author":"Nakagawa","year":"2015","journal-title":"Methods Ecol Evol"},{"key":"2021102118064328500_CIT0013","article-title":"Detecting heterogeneity of intervention effects using analysis and meta-analysis of differences in variance between arms of a trial","author":"Mills","year":"2020","journal-title":"MedRxiv."},{"issue":"12","key":"2021102118064328500_CIT0014","doi-asserted-by":"crossref","first-page":"e034816","DOI":"10.1136\/bmjopen-2019-034816","article-title":"What are the chances for personalised treatment with antidepressants? Detection of patient-by-treatment interaction with a variance ratio meta-analysis","volume":"9","author":"Pl\u00f6derl","year":"2019","journal-title":"BMJ Open."},{"key":"2021102118064328500_CIT0015","article-title":"On the treatment effect heterogeneity of antidepressants in major depression. A Bayesian meta-analysis","author":"Volkmann","year":"2020","journal-title":"MedRxiv"},{"key":"2021102118064328500_CIT0016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neubiorev.2020.11.033","article-title":"Treatment effect variability in brain stimulation across psychiatric disorders: a meta-analysis of variance","volume":"124","author":"Homan","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"key":"2021102118064328500_CIT0017","article-title":"On the relationship between treatment effect heterogeneity and the variability ratio effect size statistic","author":"Volkmann","year":"2020"},{"issue":"2","key":"2021102118064328500_CIT0018","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamapsychiatry.2019.3382","article-title":"Is Variance Ratio a valid indicator of heterogeneous treatment effect?-Reply","volume":"77","author":"Winkelbeiner","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"2021102118064328500_CIT0019","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41386-019-0322-y","article-title":"Structural similarity networks predict clinical outcome in early-phase psychosis","volume":"44","author":"Homan","year":"2019","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"2021102118064328500_CIT0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry."},{"issue":"5","key":"2021102118064328500_CIT0021","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med."},{"issue":"6","key":"2021102118064328500_CIT0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jama.1995.03520300035033","article-title":"Weight, weight change, and coronary heart disease in women. Risk within the \u2018normal\u2019 weight range","volume":"273","author":"Willett","year":"1995","journal-title":"JAMA."},{"issue":"8","key":"2021102118064328500_CIT0023","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol."},{"key":"2021102118064328500_CIT0024","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.schres.2018.04.027","article-title":"Predictors of \u2018all-cause discontinuation\u2019 of initial oral antipsychotic medication in first episode psychosis","volume":"201","author":"Mustafa","year":"2018","journal-title":"Schizophr Res."},{"key":"2021102118064328500_CIT0025","article-title":"Hyperprolactinemia.","volume-title":"StatPearls","author":"Thapa","year":"2020"},{"key":"2021102118064328500_CIT0026","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1111\/j.1743-6109.2010.01709.x","article-title":"Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics","volume":"7","author":"Bajorek","year":"2010","journal-title":"J Sex Med."},{"issue":"3","key":"2021102118064328500_CIT0027","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/YIC.0b013e328341e434","article-title":"A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics","volume":"26","author":"Serretti","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"2021102118064328500_CIT0028","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0924-9338(10)71700-4","article-title":"Physical health in schizophrenia: a challenge for antipsychotic therapy","volume":"25 Suppl 2","author":"Heald","year":"2010","journal-title":"Eur Psychiatry."},{"key":"2021102118064328500_CIT0029","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/tp.2012.114","article-title":"Cerebral blood flow identifies responders to transcranial magnetic stimulation in auditory verbal hallucinations","volume":"2","author":"Homan","year":"2012","journal-title":"Transl Psychiatry."},{"key":"2021102118064328500_CIT0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.schres.2018.02.051","article-title":"Neuroimaging of formal thought disorder in schizophrenia: a systematic review","author":"Cavelti","year":"2018","journal-title":"Schizopr Res"},{"key":"2021102118064328500_CIT0031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pscychresns.2018.05.011","article-title":"Formal thought disorder is related to aberrations in language-related white matter tracts in patients with schizophrenia","volume":"279","author":"Cavelti","year":"2018","journal-title":"Psychiatry Res Neuroimaging."},{"key":"2021102118064328500_CIT0032","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.schres.2018.06.009","article-title":"Decreased blood flow in the right insula and middle temporal gyrus predicts negative formal thought disorder in schizophrenia","volume":"201","author":"Winkelbeiner","year":"2018","journal-title":"Schizophr Res."},{"key":"2021102118064328500_CIT0033","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.psychres.2016.02.070","article-title":"The impact of thought disorder on therapeutic alliance and personal recovery in schizophrenia and schizoaffective disorder: an exploratory study","volume":"239","author":"Cavelti","year":"2016","journal-title":"Psychiatry Res."},{"issue":"3","key":"2021102118064328500_CIT0034","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1176\/appi.ajp.2019.1760501","article-title":"QTc Prolongation and psychotropic medications","volume":"177","author":"Funk","year":"2020","journal-title":"Am J Psychiatry."},{"key":"2021102118064328500_CIT0035","first-page":"5","article-title":"Schizophrenia, antipsychotic drugs, and cardiovascular disease","volume":"66 Suppl 6","author":"Glassman","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"2021102118064328500_CIT0036","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","article-title":"Risk factors for QTc-prolongation: systematic review of the evidence","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm."},{"issue":"5","key":"2021102118064328500_CIT0037","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/08039480801959323","article-title":"Schizophrenia and sudden cardiac death: a review","volume":"62","author":"Koponen","year":"2008","journal-title":"Nord J Psychiatry."},{"issue":"1","key":"2021102118064328500_CIT0038","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med Res Methodol."},{"issue":"11","key":"2021102118064328500_CIT0039","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"2021102118064328500_CIT0040","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"Stat Software"},{"issue":"1-3","key":"2021102118064328500_CIT0041","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr Res."},{"key":"2021102118064328500_CIT0042","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"issue":"12","key":"2021102118064328500_CIT0043","first-page":"783","article-title":"Evaluation of loxapine succinate in chronic schizophrenia","volume":"33","author":"Clark","year":"1972","journal-title":"Dis Nerv Syst."},{"issue":"6","key":"2021102118064328500_CIT0044","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4088\/JCP.v68n0603","article-title":"Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"68","author":"Kahn","year":"2007","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"2021102118064328500_CIT0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"issue":"1-3","key":"2021102118064328500_CIT0046","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res."},{"issue":"2","key":"2021102118064328500_CIT0047","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int Clin Psychopharmacol."},{"issue":"2","key":"2021102118064328500_CIT0048","first-page":"54","article-title":"Efficacy and safety of paliperidone extended release 1.5 mg\/day-a double-blind, placebo- and active-controlled, study in the treatment of patients with Schizophrenia","volume":"44","author":"Coppola","year":"2011","journal-title":"Psychopharmacol Bull."},{"issue":"4","key":"2021102118064328500_CIT0049","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1017\/S1092852916000377","article-title":"Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control","volume":"22","author":"Landbloom","year":"2017","journal-title":"CNS Spectr."},{"issue":"3","key":"2021102118064328500_CIT0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"2021102118064328500_CIT0051","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF02245618","article-title":"A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia","volume":"124","author":"van Kammen","year":"1996","journal-title":"Psychopharmacology"},{"issue":"4","key":"2021102118064328500_CIT0052","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry."},{"issue":"9","key":"2021102118064328500_CIT0053","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin Neurosci."},{"issue":"9","key":"2021102118064328500_CIT0054","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am J Psychiatry."},{"key":"2021102118064328500_CIT0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0006-3223(95)94656-H","article-title":"Efficacy and safety of sertindole in a trial of schizophrenic patients","volume":"9","author":"Zborowski","year":"1995","journal-title":"Biol Psychiatry"},{"issue":"2 Suppl 1","key":"2021102118064328500_CIT0056","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies","volume":"28","author":"Potkin","year":"2008","journal-title":"J Clin Psychopharmacol."},{"issue":"6","key":"2021102118064328500_CIT0057","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"2021102118064328500_CIT0058","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"2021102118064328500_CIT0059","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berl)."},{"issue":"4","key":"2021102118064328500_CIT0060","first-page":"37","article-title":"A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned","volume":"43","author":"Cutler","year":"2010","journal-title":"Psychopharmacol Bull."},{"issue":"5","key":"2021102118064328500_CIT0061","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/cpt1970115680","article-title":"Molindone in chronic schizophrenia","volume":"11","author":"Clark","year":"1970","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"2021102118064328500_CIT0062","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group","volume":"16","author":"Borison","year":"1996","journal-title":"J Clin Psychopharmacol."},{"key":"2021102118064328500_CIT0063","first-page":"417","article-title":"Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or olanzapine: a comparison of results","volume":"33","author":"Ahmed","year":"2007","journal-title":"Schizophrenia Bull"},{"key":"2021102118064328500_CIT0064","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo-and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2021102118064328500_CIT0065","first-page":"446","article-title":"A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia","volume":"33","author":"Meltzer","year":"2007","journal-title":"Schizophrenia Bull"},{"issue":"6","key":"2021102118064328500_CIT0066","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry."},{"issue":"2","key":"2021102118064328500_CIT0067","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia","volume":"30","author":"Kane","year":"2010","journal-title":"J Clin Psychopharmacol."},{"issue":"9","key":"2021102118064328500_CIT0068","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"2021102118064328500_CIT0069","first-page":"2077","article-title":"A double-blind, placebo-controlled, comparative study of paliperidone extended release (ER) tablets in patients with schizophrenia","volume":"13","author":"Hirayasu","year":"2010","journal-title":"Japanese J Psychopharmacol"},{"issue":"5","key":"2021102118064328500_CIT0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"2021102118064328500_CIT0071","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1034\/j.1600-0447.2000.101003218.x","article-title":"A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia","volume":"101","author":"Cooper","year":"2000","journal-title":"Acta Psychiatr Scand."},{"issue":"3","key":"2021102118064328500_CIT0072","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","article-title":"Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology (Berl)."},{"key":"2021102118064328500_CIT0073","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia\u2013results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"2021102118064328500_CIT0074","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med."},{"key":"2021102118064328500_CIT0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of Schizophrenia: a 4-week randomized, double-blind, controlled trial","author":"Lieberman","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"7","key":"2021102118064328500_CIT0076","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry."},{"issue":"2-3","key":"2021102118064328500_CIT0077","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res."},{"issue":"5","key":"2021102118064328500_CIT0078","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J Psychiatr Res."},{"issue":"12","key":"2021102118064328500_CIT0079","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry."},{"issue":"2","key":"2021102118064328500_CIT0080","first-page":"213","article-title":"Risperidone: clinical safety and efficacy in schizophrenia","volume":"28","author":"Borison","year":"1992","journal-title":"Psychopharmacol Bull."},{"key":"2021102118064328500_CIT0081","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia","volume":"53","author":"Shen","year":"2014","journal-title":"J Psychiatr Res."},{"issue":"14","key":"2021102118064328500_CIT0082","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00213-016-4295-9","article-title":"Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study","volume":"233","author":"Kinoshita","year":"2016","journal-title":"Psychopharmacology (Berl)."},{"issue":"11","key":"2021102118064328500_CIT0083","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"J Psychiatr Res."},{"issue":"1-3","key":"2021102118064328500_CIT0084","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res."},{"key":"2021102118064328500_CIT0085","first-page":"S515","article-title":"Is quality of life related to cognitive performance or negative symptoms in patients with schizophrenia? Results from a double-blind, active-controlled, lurasidone extension study","volume":"38","author":"Harvey","year":"2013","journal-title":"Neuropsychopharmacology."},{"issue":"9","key":"2021102118064328500_CIT0086","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry."},{"issue":"5","key":"2021102118064328500_CIT0087","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0b013e3181eeb600","article-title":"Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and\/or mood stabilizers","volume":"30","author":"Canuso","year":"2010","journal-title":"J Clin Psychopharmacol."},{"issue":"6","key":"2021102118064328500_CIT0088","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/2045125315606027","article-title":"A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia","volume":"5","author":"Potkin","year":"2015","journal-title":"Ther Adv Psychopharmacol."},{"issue":"1-2","key":"2021102118064328500_CIT0089","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology (Berl)."},{"issue":"5","key":"2021102118064328500_CIT0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","article-title":"A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder","volume":"71","author":"Canuso","year":"2010","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"2021102118064328500_CIT0091","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology."},{"issue":"12","key":"2021102118064328500_CIT0092","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with Schizophrenia: a randomized, placebo-controlled study","volume":"77","author":"Loebel","year":"2016","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"2021102118064328500_CIT0093","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JCP.0000000000000071","article-title":"The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study","volume":"34","author":"Litman","year":"2014","journal-title":"J Clin Psychopharmacol."},{"issue":"1-3","key":"2021102118064328500_CIT0094","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr Res."},{"issue":"3","key":"2021102118064328500_CIT0095","first-page":"11","article-title":"The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study","volume":"41","author":"Lindenmayer","year":"2008","journal-title":"Psychopharmacol Bull."},{"issue":"4","key":"2021102118064328500_CIT0096","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of Schizophrenia: results from an international, Phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol."},{"issue":"1-3","key":"2021102118064328500_CIT0097","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr Res."},{"issue":"6","key":"2021102118064328500_CIT0098","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry."},{"key":"2021102118064328500_CIT0099","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euroneuro.2012.02.007","article-title":"A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia","volume":"22","author":"Schmidt","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021102118064328500_CIT0100","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.4088\/JCP.12m07642","article-title":"Bl-1020, a new -aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study","volume":"73","author":"Geffen","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2021102118064328500_CIT0101","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","article-title":"Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group","volume":"154","author":"Zimbroff","year":"1997","journal-title":"Am J Psychiatry."},{"key":"2021102118064328500_CIT0102","first-page":"22","article-title":"A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia","author":"Center for Drug Evaluation and Research.","year":"2009","journal-title":"Med Rev"},{"key":"2021102118064328500_CIT0103","first-page":"23","article-title":"A multicenter, randomized, double-blind, flexible-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia","author":"Center for Drug Evaluation and Research.","year":"2009","journal-title":"Med Rev"},{"key":"2021102118064328500_CIT0104","first-page":"21","article-title":"Study 9420 2002","volume":"S9","author":"Center for Drug Evaluation and Research.","year":"2002","journal-title":"Med Rev"},{"key":"2021102118064328500_CIT0105","first-page":"20","article-title":"Study 115 2000","volume":"S1","author":"Center for Drug Evaluation and Research.","year":"2000","journal-title":"Med Rev"},{"issue":"4","key":"2021102118064328500_CIT0106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/acps.12965","article-title":"Clozapine as an early-stage treatment","volume":"138","author":"Homan","year":"2018","journal-title":"Acta Psychiatr Scand."},{"issue":"10","key":"2021102118064328500_CIT0107","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1177\/0269881118780011","article-title":"Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database","volume":"32","author":"Osborn","year":"2018","journal-title":"J Psychopharmacol."},{"issue":"6","key":"2021102118064328500_CIT0108","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res."},{"issue":"6","key":"2021102118064328500_CIT0109","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/acps.12737","article-title":"Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study","volume":"135","author":"Najar","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"2021102118064328500_CIT0110","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008016.pub2","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2021102118064328500_CIT0111","article-title":"Relapse prevention through health technology program reduces hospitalization in schizophrenia","author":"Homan","year":"2019.","journal-title":"bioRxiv"},{"issue":"2","key":"2021102118064328500_CIT0112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2015.2582","article-title":"Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment","volume":"73","author":"Nielsen","year":"2016","journal-title":"JAMA Psychiatry."},{"key":"2021102118064328500_CIT0113","article-title":"Antipsychotic-Induced Hyperpro lactinaemia. Austr N Z J Psychiatry. 2011;45(10):830-837","author":"Inder"},{"issue":"6","key":"2021102118064328500_CIT0114","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev."},{"issue":"Pt 4","key":"2021102118064328500_CIT0115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1258\/acb.2010.010025","article-title":"A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?","volume":"47","author":"Bushe","year":"2010","journal-title":"Ann Clin Biochem."},{"issue":"4","key":"2021102118064328500_CIT0116","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev."},{"issue":"6","key":"2021102118064328500_CIT0117","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"2021102118064328500_CIT0118","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13058-018-0969-z","article-title":"Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions","volume":"20","author":"Johnston","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"1","key":"2021102118064328500_CIT0119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/1055-9965.EPI-19-0776","article-title":"Psychotropic medication use and postmenopausal breast cancer risk","volume":"29","author":"George","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"2","key":"2021102118064328500_CIT0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e31820e4832","article-title":"Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion","volume":"31","author":"Veselinovi\u0107","year":"2011","journal-title":"J Clin Psychopharmacol."},{"issue":"7","key":"2021102118064328500_CIT0121","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0269881109106914","article-title":"A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia","volume":"24","author":"Berwaerts","year":"2010","journal-title":"J Psychopharmacol."},{"issue":"5","key":"2021102118064328500_CIT0122","first-page":"292","article-title":"Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications","volume":"4","author":"Riordan","year":"2011","journal-title":"Am Health Drug Benefits."},{"issue":"3","key":"2021102118064328500_CIT0123","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med."},{"key":"2021102118064328500_CIT0124","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1542-474X.1997.tb00325.x","article-title":"An analysis of the time-relations of electrocardiograms","volume":"2","author":"Bazett","year":"1997","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"11","key":"2021102118064328500_CIT0125","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry."},{"issue":"6","key":"2021102118064328500_CIT0126","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","article-title":"Assessing QT interval prolongation and its associated risks with antipsychotics","volume":"25","author":"Nielsen","year":"2011","journal-title":"CNS Drugs."},{"issue":"4","key":"2021102118064328500_CIT0127","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00406-018-0880-8","article-title":"QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors","volume":"268","author":"Spellmann","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/47\/6\/1601\/40809877\/sbab078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/47\/6\/1601\/40809877\/sbab078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T14:45:46Z","timestamp":1634827546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/47\/6\/1601\/6347162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":127,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,8,10]]},"published-print":{"date-parts":[[2021,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbab078","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.27.20162727","asserted-by":"object"}]},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,10]]}}}